MedTrace Logo

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

NCT07408232 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-19

No results posted yet for this study

Summary

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.

Conditions

Interventions

DRUG

Phase 1a: OCT-980 Capsule

OCT-980 capsules administered orally once at dose levels specified in the protocol

DRUG

Phase 1a: Placebo Capsule

Placebo capsules administered orally once at dose levels specified in the protocol

DRUG

Phase 1b/2: OCT-980 Tablet

OCT-980 tablets administered orally once at dose levels specified in the protocol

Sponsors & Collaborators

  • Octant, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2028-11-01
Completion
2028-11-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408232 on ClinicalTrials.gov